LinkedIn · Feb 2026
A LinkedIn post highlighted Helen Chen speaking in a healthcare-track session and reiterated Alixia's precision-oncology focus.
Targeting the Tumor Ecosystem to address cancer drug resistance.
Company research
Public company, workplace, funding, and market signals
Overview
Alixia is a San Francisco biotech/precision-oncology startup developing tumor-ecosystem disruptors to combat cancer drug resistance by targeting the tumor microenvironment; public sources describe it as founder-led and research-heavy, with some disagreement on founding year (2018 vs. 2022).
Primary product
Tumor ecosystem disruptors for cancer drug resistance
Founded
2022
Headquarters
San Francisco, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Oncology therapeutics / precision oncology
Offices
953 Indiana Street, San Francisco, CA 94107
Open Positions
0 jobs at Alixia
No open positions
Check back later for new openings